La assay

Manufactured by Roche

Sourced in United States

The LA assay is a laboratory equipment product that performs Luminescence Assays. It is designed to accurately measure and analyze luminescent signals, which are commonly used in a variety of research and diagnostic applications.

Automatically generated - may contain errors

Lab products found in correlation

Thinprep preservcyt solution, by Hologic (1 mentions) Qiaamp minelute media kit, by Qiagen (1 mentions) Magna pure lc total nucleic acid isolation kit, by Roche (1 mentions)

Spelling variants of this product

Linear Array HPV genotyping assay (LA-HPV) (3 citations) Linear Array HPV genotyping assay (LA-HP; (2 citations)

2 protocols using la assay

HPV Genotyping Using Consensus PCR Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human papillomavirus genotypes in cervical samples were determined using the LA assay (Roche Molecular Systems) in the MINT study I and the PGMY‐CHUV assay in the MINT study II. Both assays are L1 consensus primer‐based PCR methods that use a primer set designated as PGMY09/11.¹⁹ Details of these HPV genotyping assays have been provided elsewhere.²⁰ Briefly, exfoliated ectocervical and endocervical cells were stored in ThinPrep PreservCyt solution (Hologic) until DNA extraction. Total cellular DNA was extracted using a QIAamp MinElute Media kit (Qiagen) in the MINT study I and a MagNA Pure LC Total Nucleic Acid Isolation kit (Roche) in the MINT study II. The PGMY PCR products were subjected to reverse line blot hybridization for both methods. The LA assay detects 37 individual HPV genotypes, and the PGMY‐CHUV assay detects 31 genotypes. The two assays detect 28 genotypes in common (HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 66, 68, 69, 70, 73, 82, 83, and 84).
All HPV DNA assays were carried out by individuals masked to the results and clinical profile of each patient.

Onuki M., Yamamoto K., Yahata H., Kanao H., Yokota H., Kato H., Shimamoto K., Takehara K., Kamiura S., Tsuda N., Takei Y., Shigeta S., Matsumura N., Yoshida H., Motohara T., Watari H., Nakamura K., Ueda A., Tasaka N., Ishikawa M., Hirashima Y., Kudaka W., Taguchi A., Iwata T., Takahashi F., Kukimoto I., Yoshikawa H., Yaegashi N, & Matsumoto K. (2022). Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women. Cancer Science, 113(4), 1428-1434.

+ Open protocol

+ Expand

HPV Genotyping by LA Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

The LA assay (Roche Molecular Systems, Pleasanton, CA, USA) was carried out according to the manufacturer's recommended protocol. Briefly, an aliquot (20 μL) of the purified DNA was used for PCR amplification with PGMY09/11 primers. The PCR products were subjected to reverse line blot hybridization for detection of 37 individual HPV genotypes (HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51 to 56, 58, 59, 61, 62, 64, 66 to 73, 81 to 84, and 89) . LA detects nine additional HPV genotypes not detected by PGMY-CHUV: HPV61, 62, 64, 67, 71, 72, 81, 82 (IS39) and 89 (CP6108). HPV genotyping using LA was performed at a clinical testing laboratory (SRL, Tokyo, Japan). Genotypes determined by PGMY-CHUV were recorded prior to the disclosure of LA results. The LA assays were performed by individuals who were blinded to the PGMY-CHUV results.

Kukimoto I., Matsumoto K., Takahashi F., Iwata T., Tanaka K., Yamaguchi-Naka M., Yamamoto K., Yahata H., Nakabayashi M., Kato H., Tsuda N., Onuki M, & Yaegashi N. (2020). Human Papillomavirus (HPV) Genotyping Assay Suitable for Monitoring the Impact of the 9-Valent HPV Vaccine. The Tohoku journal of experimental medicine, 251(4).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!